Metabolic Dysfunction-Associated Fatty Liver Disease on Distinct Microbial Communities at the Bacterial Phylum Level

被引:2
|
作者
Uojima, Haruki [1 ,2 ]
Sakaguchi, Yoshihiko [3 ]
Gotoh, Kazuyoshi [4 ]
Satoh, Takashi [5 ]
Hidaka, Hisashi [1 ]
Take, Akira [3 ]
Horio, Kazue [1 ]
Hayashi, Shunji [3 ]
Kusano, Chika [1 ]
机构
[1] Kitasato Univ, Sch Med, Dept Gastroenterol, Internal Med, Sagamihara, Japan
[2] Natl Ctr Global Hlth & Med, Dept Genome Med Sci Project, Res Inst, Ichikawa, Japan
[3] Kitasato Univ, Sch Med, Dept Microbiol, Sagamihara, Japan
[4] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Bacteriol, Okayama, Japan
[5] Kitasato Univ, Sch Allied Hlth Sci, Div Hematol, Sagamihara, Japan
关键词
Firmicutes; Liver cirrhosis; Metabolic dysfunction-associated fatty liver disease; Fecal microbial communities; Dysbiosis; GUT MICROBIOTA; STEATOSIS; SEVERITY; FIBROSIS;
D O I
10.1159/000534284
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Introduction: Limited data are available on the correlation between microbial communities and metabolic dysfunction-associated fatty liver disease (MAFLD). This study aimed to evaluate the influence of MAFLD on diverse microbial communities. Methods: We recruited 43 patients with a nonviral liver disease. Enrolled patients were divided into two groups according to MAFLD criteria. The fecal microbial composition was evaluated using the variable V3-V4 region of the 16S ribosomal RNA region, which was amplified using polymerase chain reaction. First, we assessed the influence of MAFLD on distinct microbial communities at the bacterial phylum level. Next, the correlation between the microbial communities and diversity in patients with MAFLD was evaluated. Results: Among the enrolled participants, the non-MAFLD and MAFLD groups consisted of 21 and 22 patients, respectively. Sequences were distributed among ten bacterial phyla. The relative abundance of Firmicutes was significantly higher in the MAFLD group than in the non-MAFLD group (p = 0.014). The microbial diversity was not significantly influenced by the presence of MAFLD (Chao-1 index: p = 0.215 and Shannon index: p = 0.174, respectively); nonetheless, the correlation coefficient between the abundances of Firmicutes and microbial diversity was higher in the non-MAFLD group than in the MAFLD group. Conclusion: The presence of MAFLD increased the relative abundances of Firmicutes at the bacterial phylum level, which may cause the discrepancy between the abundances of Firmicutes and diversity in patients with MAFLD.
引用
收藏
页码:61 / 69
页数:9
相关论文
共 50 条
  • [21] Quality of Life in Adults with Metabolic Dysfunction-Associated Fatty Liver Disease
    Hwang, Tae-In
    Han, A-Lum
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (24)
  • [22] Transition of an acronym from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease
    Alam, Shahinul
    Fahim, Shah Mohammad
    WORLD JOURNAL OF HEPATOLOGY, 2021, 13 (10) : 1203 - 1207
  • [23] Transition of an acronym from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease
    Shahinul Alam
    Shah Mohammad Fahim
    World Journal of Hepatology, 2021, 13 (10) : 1203 - 1207
  • [24] Updates in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) in Children
    Rupasinghe, Kushila
    Hind, Jonathan
    Hegarty, Robert
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2023, 77 (05): : 583 - 591
  • [25] Are dairy products the answer to metabolic dysfunction-associated fatty liver disease?
    Lau, Kristopher Cho-Hei
    Wong, Vincent Wai-Sun
    HEPATOLOGY INTERNATIONAL, 2024, 18 (03) : 870 - 872
  • [26] The Relationship Between Ferroptosis and Metabolic Dysfunction-Associated Fatty Liver Disease
    Chen, Ke-qian
    Wang, Shu-zhi
    Lei, Hai-bo
    Liu, Xiang
    LIVER INTERNATIONAL, 2025, 45 (04)
  • [27] Metabolic dysfunction-associated fatty liver disease and chronic hepatitis B
    Huang, Shang -Chin
    Kao, Jia-Horng
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2022, 121 (11) : 2148 - 2151
  • [28] Metabolic dysfunction-associated fatty liver disease: current therapeutic strategies
    Al Hashmi, Khamis
    Giglio, Rosaria Vincenza
    Stoian, Anca Pantea
    Patti, Angelo Maria
    Al Waili, Khalid
    Al Rasadi, Khalid
    Ciaccio, Marcello
    Rizzo, Manfredi
    FRONTIERS IN NUTRITION, 2024, 11
  • [29] Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma
    Song, Byeong Geun
    Choi, Sung Chul
    Goh, Myung Ji
    Kang, Wonseok
    Sinn, Dong Hyun
    Gwak, Geum-Youn
    Paik, Yong-Han
    Choi, Moon Seok
    Lee, Joon Hyeok
    Paik, Seung Woon
    JHEP REPORTS, 2023, 5 (09)
  • [30] Metabolic dysfunction-associated fatty liver disease in people living with HIV
    Michel, Maurice
    Labenz, Christian
    Armandi, Angelo
    Kaps, Leonard
    Kremer, Wolfgang Maximilian
    Galle, Peter R.
    Grimm, Daniel
    Sprinzl, Martin
    Schattenberg, Joern M.
    SCIENTIFIC REPORTS, 2023, 13 (01)